137 related articles for article (PubMed ID: 20855974)
1. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
[TBL] [Abstract][Full Text] [Related]
2. Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer?
Keller JA; Erson-Bensan AE; Petty EM
Cancer Biol Ther; 2010 Nov; 10(9):942-4. PubMed ID: 21057211
[No Abstract] [Full Text] [Related]
3. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer.
Koga T; Takeshita M; Yano T; Maehara Y; Sueishi K
Int J Cancer; 2011 Mar; 128(5):1009-17. PubMed ID: 20473935
[TBL] [Abstract][Full Text] [Related]
4. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
[TBL] [Abstract][Full Text] [Related]
5. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
7. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
[TBL] [Abstract][Full Text] [Related]
8. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.
Ogi K; Toyota M; Mita H; Satoh A; Kashima L; Sasaki Y; Suzuki H; Akino K; Nishikawa N; Noguchi M; Shinomura Y; Imai K; Hiratsuka H; Tokino T
Cancer Biol Ther; 2005 Jul; 4(7):773-80. PubMed ID: 16123600
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
Yoshida K; Hamai Y; Suzuki T; Sanada Y; Oue N; Yasui W
Anticancer Res; 2006; 26(1A):49-54. PubMed ID: 16475678
[TBL] [Abstract][Full Text] [Related]
12. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.
Gao YJ; Xin Y; Zhang JJ; Zhou J
World J Gastroenterol; 2008 Aug; 14(32):5000-7. PubMed ID: 18763281
[TBL] [Abstract][Full Text] [Related]
13. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract][Full Text] [Related]
14. Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project.
Brodie SA; Li G; Brandes JC
Respir Med; 2015 Jan; 109(1):131-6. PubMed ID: 25477232
[TBL] [Abstract][Full Text] [Related]
15. The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
Zhang X; Feng Y; Wang XY; Zhang YN; Yuan CN; Zhang SF; Shen YM; Fu YF; Zhou CY; Li X; Cheng XD; Lu WG; Xie X
Cell Death Dis; 2018 Jan; 9(2):93. PubMed ID: 29367628
[TBL] [Abstract][Full Text] [Related]
16. CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes.
Koga T; Takeshita M; Ijichi K; Yano T; Maehara Y; Sueishi K
Hum Pathol; 2013 Jul; 44(7):1382-90. PubMed ID: 23415374
[TBL] [Abstract][Full Text] [Related]
17. CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes.
Takeshita M; Koga T; Takayama K; Kouso H; Nishimura-Ikeda Y; Yoshino I; Maehara Y; Nakanishi Y; Sueishi K
Int J Cancer; 2008 Oct; 123(7):1623-30. PubMed ID: 18623126
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
[TBL] [Abstract][Full Text] [Related]
20. CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer.
Guo M; Alumkal J; Drachova T; Gao D; Marina SS; Jen J; Herman JG
Discov Med; 2015 Mar; 19(104):151-8. PubMed ID: 25828518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
